Haruyoshi Tanaka
Overview
Explore the profile of Haruyoshi Tanaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iizuka A, Kanda M, Sato Y, Shimizu D, Umeda S, Tanaka H, et al.
Ann Surg Oncol
. 2025 Mar;
PMID: 40080367
Background: Transcriptome analysis of primary tumor tissues from esophageal squamous cell carcinoma (ESCC) patients with early postoperative distant metastasis identified nuclear receptor subfamily 0, group B, member 1 (NR0B1) as...
2.
Agatsuma Y, Shimizu D, Umeda S, Tanaka H, Hattori N, Hayashi M, et al.
Cancer Genomics Proteomics
. 2024 Dec;
22(1):55-69.
PMID: 39730183
Background/aim: The development of new biomarkers to predict cancer patient prognosis is expected to aid in treatment selection, contributing to improved outcomes. In this study, we extracted a candidate gene...
3.
Shirai Y, Kimura N, Tanaka H, Fukasawa M, Muranushi R, Watanabe T, et al.
Pancreas
. 2024 Dec;
PMID: 39626192
Background: Liver recurrence after resection is one of the most common types of recurrence and is a risk factor for poor prognosis. The aim of this study was to identify...
4.
Otsu T, Takami H, Yamada S, Nakatochi M, Fujita K, Tashiro M, et al.
Pancreas
. 2024 Dec;
PMID: 39626189
Objectives: Gemcitabine and nab-paclitaxel combination therapy (GnP) is a standard treatment for unresectable or recurrent pancreatic cancer. However, fatigue and malaise are frequent adverse effects. Recently, Kampo medicine containing ginsenoside...
5.
Araki T, Muranushi R, Takagi K, Tanaka H, Shibuya K, Ando T, et al.
Clin J Gastroenterol
. 2024 Oct;
18(1):161-168.
PMID: 39436624
We report a rare case of a patient with initially unresectable gallbladder cancer who underwent conversion surgery with durvalumab in combination with gemcitabine plus cisplatin and achieved an R0 resection....
6.
Baba H, Oba A, Tanaka K, Miura T, Ban D, Edanami M, et al.
BMC Surg
. 2024 Oct;
24(1):314.
PMID: 39415231
Background: Postoperative pancreatic fistula (POPF) continues to be the most common complication after distal pancreatectomy (DP). Recent advancements in surgical techniques have established minimally invasive distal pancreatectomy (MIDP) as the...
7.
Ito M, Watanabe T, Oga Y, Matsumoto S, Kimura N, Nagamori M, et al.
Clin J Gastroenterol
. 2024 Oct;
18(1):208-213.
PMID: 39402396
A 72-year-old woman was diagnosed with unresectable pancreatic body-tail cancer (cT4N1M1, cStage IV) with para-aortic lymph node metastasis. She underwent six courses of gemcitabine + nab-paclitaxel as first-line chemotherapy, 12...
8.
Kimura N, Igarashi T, Murotani K, Itoh A, Watanabe T, Hirano K, et al.
Ann Gastroenterol Surg
. 2024 Mar;
8(2):301-311.
PMID: 38455496
Background: There have been few studies of countermeasures against postoperative cholangitis, a serious complication after pancreaticoduodenectomy (PD) that impairs quality of life. Objective: To evaluate our recently developed, novel method...
9.
Igarashi T, Fukasawa M, Watanabe T, Kimura N, Itoh A, Tanaka H, et al.
Ann Gastroenterol Surg
. 2024 Jan;
8(1):124-132.
PMID: 38250680
Introduction: The prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of staging laparoscopy (SL) and treatment...
10.
Fukasawa M, Watanabe T, Tanaka H, Itoh A, Kimura N, Shibuya K, et al.
J Hepatobiliary Pancreat Sci
. 2023 Sep;
30(11):1261-1272.
PMID: 37750024
Background: The frequency and prognosis of positive peritoneal washing cytology (CY1) in resectable pancreatic ductal adenocarcinoma (R-PDAC) remains unclear. The objective of this study was to identify the clinical implications...